Pharmacy Transparency Your provider must disclose: Which pharmacy compounds or dispenses your peptides (name and location) Pharmacy type (503A or 503B) and FDA registration status Quality testing performed (purity, sterility, endotoxin testing) Certificates of Analysis available upon request Sourcing of raw peptide materials (US-manufactured preferred) Warning sign: Providers who are evasive about pharmacy sourcing or claim proprietary pharmacy relationships are likely using questionable sources
Expect significant measurement variability between tests
Ferroptosis as an emerging target in rheumatoid arthritis
[DOI] [PMC free article] [PubMed] [Google Scholar] Smeets K, Opdenakker K, Remans T, van Sanden S, van Belleghem F, Semane B, Horemans N, Guisez Y, Vangronsveld J, Cuypers A
MOTS-C Dosage Chart: Week-by-Week Titration Protocol No universally accepted clinical dosing standard for MOTS-c exists yet, and any protocol should be developed in consultation with a licensed physician familiar with peptide therapeutics
